Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medigen Biotechnology's Revenue for the
three
months ended in Mar. 2026 was NT$261 Mil. Medigen Biotechnology's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$186 Mil.
Hence, Medigen Biotechnology's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.41.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medigen Biotechnology Receivables Turnover Related Terms
Medigen Biotechnology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Receivables Turnover of 1.41 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medigen Biotechnology and its competitors. According to the industry distribution chart, Medigen Biotechnology ranks #340 out of 841 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Medigen Biotechnology's Receivables Turnover too high?
Medigen Biotechnology's current Receivables Turnover is 1.41. The Biotechnology industry median Receivables Turnover is 5.27. Medigen Biotechnology's value of 1.41 is 73.2% below this industry median. Based on the distribution chart, Medigen Biotechnology ranks #340 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Biotechnology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #340 out of 841 companies for Receivables Turnover. This puts Medigen Biotechnology in the upper half of its industry. The industry median Receivables Turnover is 5.27. Medigen Biotechnology's value of 1.41 is 73.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Biotechnology's current Receivables Turnover of 1.41 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current Receivables Turnover is 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Fairly Valued. The stock's GF Value™ is NT$36.89, compared to a current price of NT$33.70 — trading 8.6% below its estimated fair value. The current Receivables Turnover is 1.41 and 73.2% below the Biotechnology industry median of 5.27. Medigen Biotechnology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Receivables Turnover is 1.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$33.70 is trading 8.6% below its estimated GF Value™ of NT$36.89.
GuruFocus considers Medigen Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3176:
Receivables Turnover: 1.41
GF Value™: NT$36.89 vs. price of NT$33.70 (8.6% below fair value)
Industry Position: 73.2% below the Biotechnology median (#340 of 841)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
55GF Score
Get the complete analysis for ROCO:3176
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
